
Epicure25 mg
Incepta Pharmaceuticals Ltd.
Brivaracetam is a synaptic vesicle protein 2A (SV2A) ligand antiepileptic drug (AED).
Brivaracetam is a synaptic vesicle protein 2A (SV2A) ligand antiepileptic drug (AED). Its established and evidence-based uses are:
| Indication | Starting dose | Maintenance dose | Maximum dose |
|---|---|---|---|
| Partial-onset seizures (adjunctive or monotherapy) | 50 mg twice daily (100 mg/day) | 25–100 mg twice daily, adjusted based on response and tolerability | 200 mg/day |
| Body weight | Starting dose | Maintenance range |
|---|---|---|
| Less than 11 kg | 0.75 mg/kg twice daily | 0.75–3 mg/kg twice daily |
| 11 kg to less than 20 kg | 0.5 mg/kg twice daily | 0.5–2.5 mg/kg twice daily |
| 20 kg to less than 50 kg | 0.5 mg/kg twice daily | 0.5–2 mg/kg twice daily |
| 50 kg or more | Same as adult dosing | Same as adult dosing |
Common side effects of Brivaracetam (occurring in clinical trials at meaningfully higher rates than placebo) include:
Serious but less common effects requiring prompt medical attention:
Brivaracetam is contraindicated in patients with a known hypersensitivity to Brivaracetam or to any of its formulation excipients.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.